ArticleHaematologica2017
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.HemaSphere · 2026Article
- Article
- T-lymphocytes suppression by CD14Journal of translational medicine · 2025Article
- Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives.Journal of bone oncology · 2025Review
- A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insights.Blood and lymphatic cancer : targets and therapy · 2025Article
- An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma.Clinical and experimental medicine · 2024Article
- Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.Nature cancer · 2023Article
- Review
- Origin of Osteoclasts: Osteoclast Precursor Cells.Journal of bone metabolism · 2023Article
- Article
- Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.Scientific reports · 2022Article
- Distinct phenotype of neutrophil, monocyte, and eosinophil populations indicates altered myelopoiesis in a subset of patients with multiple myeloma.Frontiers in oncology · 2022Article
- Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells.Frontiers in oncology · 2022Article
- The Rising Era of "Immunoporosis": Role of Immune System in the Pathophysiology of Osteoporosis.Journal of inflammation research · 2022Review
- Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.Nature communications · 2021Article
- Article
- Aging-associated immune system changes in multiple myeloma: The dark side of the moon.Cancer treatment and research communications · 2021Review
- Dissecting heterogeneous cell populations across drug and disease conditions with PopAlign.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- CD14Arthritis research & therapy · 2020Article
- Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow monocytes are primarily committed to osteoclast formation. It is, however, unknown whether potential primary alterations are specifically present in bone marrow monocytes from patients with multiple myeloma, smoldering myeloma or monoclonal gammopathy of undetermined significance. We analyzed the immunophenotypic and transcriptional profiles of bone marrow CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.